Effective treatment with abciximab for consecutive bilateral middle cerebral artery occlusion.
Puetz
Volker
V
Department of Neurology, Technical University Dresden, Dresden, Germany. volker.puetz@neuro.med.tu-dresden.de
Weise
Matthias
M
von Kummer
Ruediger
R
Gahn
Georg
G
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage*; D020244:Infarction, Middle Cerebral Artery / Q000000981:diagnostic imaging / Q000188:drug therapy*; D007262:Infusions, Intravenous; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011859:Radiography; D012008:Recurrence; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D016896:Treatment Outcome; D014463:Ultrasonography
D000911:Antibodies, Monoclonal; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D010959:Tissue Plasminogen Activator; D000077284:Abciximab